Chart review across EU5 in MM post-ASCT patients.
Int J Hematol Oncol
; 7(1): IJH05, 2018 Mar.
Article
em En
| MEDLINE
| ID: mdl-30302236
ABSTRACT
AIM:
To understand the current treatment patterns, clinical outcomes and healthcare resource utilization-associated costs for multiple myeloma patients, post autologous stem cell transplant (ASCT) across Europe. PATIENTS &METHODS:
Medical records were used to abstract data for 337 multiple myeloma patients who had received ASCT.RESULTS:
Following ASCT, 7% received maintenance therapy prior to progression. Lenalidomide was the most frequently prescribed maintenance, second- and third-line therapy. Monthly resource use was considerably lower in patients who received maintenance therapy (638.14 vs 1001.74). Median time to progression was longer for patients who had received maintenance therapy.CONCLUSION:
The study highlights the diversity in current treatment patterns post-ASCT. Results suggest patients who receive maintenance therapy have a prolonged remission period, and as a result their associated healthcare resource utilization is spread across the treatment pathway.
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article